Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).

被引：2
|
作者：
Tang, Jie
Liu, XiaoLing
Gong, Youling
Zhu, Jiang
Huang, Meijuan
Ding, Zhenyu
Yu, Min
Tie, Yan
Li, Qiu
Wang, Yongsheng
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Oncol, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Canc, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21154
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Rebiopsy of patients with "acquired resistance" to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Miller, Vincent A.
    Riely, Gregory J.
    Arcila, Maria E.
    Oxnard, Geoffrey
    Zakowski, Maureen F.
    Kris, Mark G.
    Pao, William
    Ladanyi, Marc
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S314 - S314
  • [2] Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Arcila, M. E.
    Riely, G. J.
    Zakowski, M. F.
    Kris, M. G.
    Ladanyi, M.
    Pao, W.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] TOXICITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS (EGFR-TKIS) IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A META-ANALYSIS
    Ding, Pei Ni
    Lord, Sally
    Links, Matthew
    Bray, Victoria
    Gebski, Val
    Yang, James C.
    Lee, Chee Khoon
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S593 - S593
  • [4] Impact of epidermal growth factor receptor (EGFR) mutations on responsiveness of non-small cell lung cancer (NSCLC) to tyrosine kinase inhibitors (TKIS): Prospective observations
    van Zandwijk, Nico
    Mathy, Alexandre
    de Jong, Daphne
    Baas, Paul
    Burgers, Sjaak
    Nederlof, Petra
    EJC SUPPLEMENTS, 2006, 4 (06): : 14 - 15
  • [5] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CO-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND RESPONSE TO EGFR TYROSINE KINASE INHIBITORS (TKIS)
    Barnet, Megan B.
    O'Toole, Sandra
    Horvath, Lisa' G.
    Selinger, Christina
    Yu, Bing
    Trent, Ronald
    Ng, Chiu Chin
    Boyer, Michael J.
    Cooper, Wendy
    Kao, Steven
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 156 - 156
  • [6] A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCTS) ON EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITORS (EGFR-TKIS) FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Zhang, T.
    Xu, J.
    Ma, J.
    Cai, S.
    Wu, C.
    Liu, Y.
    VALUE IN HEALTH, 2014, 17 (03) : A68 - A68
  • [7] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    LUNG CANCER, 2019, 137 : 113 - 122
  • [8] Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)
    Zhu, Lulin
    Yang, Xinxin
    Wu, Shanshan
    Dong, Rong
    Yan, Youyou
    Lin, Nengming
    Zhang, Bo
    Tan, Biqin
    DRUG METABOLISM REVIEWS, 2024,
  • [9] Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy
    Aydiner, Adnan
    Sari, Murat
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] ASSOCIATIONS BETWEEN EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (EGFR-TKIS) AND VENOUS THROMBOEMBOLISM AMONG OLDER PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Byun, J. Y.
    Aiyeolemi, A. A.
    Park, C.
    VALUE IN HEALTH, 2023, 26 (06) : S45 - S45
12345